Abetimus
 | |
| Clinical data | |
|---|---|
| Trade names | Riquent |
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1632H1944N610Na156O970P156S4 |
| Molar mass | 54171.35 g·mol−1 |
  (what is this?) (verify) | |
Abetimus (trade name Riquent) is an immunosuppressant.[1] It is a synthetic biological called a tolerogen. It is made of four double-stranded oligodeoxyribonucleotides that are attached to a carrier platform and are designed to block specific B-cell anti double stranded DNA antibodies.[2] It may also complex anti dsDNA antibodies together, therefore disabling them. This way abetimus was supposed to help treat systemic lupus erythematosus and specifically lupus nephritis.
It was developed by La Jolla Pharmaceutical, who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.[3][4]
References
- ^ "Abetimus: Abetimus sodium, LJP 394". BioDrugs. 17 (3). Springer Nature Switzerland AG: 212–5. 2003. doi:10.2165/00063030-200317030-00009. PMID 12749759. S2CID 19896886.
- ^ Wallace DJ (January 2001). "Clinical and pharmacological experience with LJP-394". Expert Opinion on Investigational Drugs. 10 (1). Informa: 111–7. doi:10.1517/13543784.10.1.111. PMID 11116284. S2CID 43518002.
- ^ "Riquent Approval Status". Drugs.com. Retrieved 7 January 2017.
- ^ "Riquent". European Medicines Agency. Retrieved 7 January 2017.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |